Showing 3,421 - 3,440 results of 12,390 for search '"infection"', query time: 0.09s Refine Results
  1. 3421

    cfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infections in general practice: a study protocol for a prospective cohort study by Dorothea Dehnen, Elmo Neuberger, Jürgen in der Schmitten, Ekaterini Giagkou, Perikles Simon, Suzan Botzenhardt

    Published 2022-06-01
    “…Introduction The clinical course of patients with a SARS-CoV-2 (COVID-19) infection varies widely, from symptom-free to severe courses that can lead to death. …”
    Get full text
    Article
  2. 3422
  3. 3423

    Prevalence of Plasmid-Mediated Quinolone Resistance Determinants and OqxAB Efflux Pumps among Extended-Spectrum β-Lactamase Producing Klebsiella pneumoniae Isolated from Patients with Nosocomial Urinary Tract Infection in Tehran, Iran by Mehdi Goudarzi, Mehdi Azad, Sima Sadat Seyedjavadi

    Published 2015-01-01
    “…The aim of this study was to investigate PMQR determinants among extended-spectrum β-lactamases- (ESBL-) producing Klebsiella pneumoniae recovered from patients with nosocomial urinary tract infection (UTI). Methods. A total of 247 ESBL-producing K. pneumoniae isolates were collected from 750 patients with UTI. …”
    Get full text
    Article
  4. 3424
  5. 3425
  6. 3426
  7. 3427
  8. 3428
  9. 3429
  10. 3430
  11. 3431
  12. 3432
  13. 3433
  14. 3434
  15. 3435
  16. 3436

    World Health Organization priority antimicrobial resistance in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecium healthcare-associated bloodstream infections in Brazil (ASCENSION): a prospective, multicentre, observational studyResearch in context by Laura C. Antochevis, Camila M. Wilhelm, Beatriz Arns, Daniel Sganzerla, Letícia O. Sudbrack, Thais C.R.L. Nogueira, Ricardo D. Guzman, Amanda S. Martins, Daniela S. Cappa, Ândrea C. dos Santos, Joseani C. Pascual, Vitor Hugo Perugini, Eliana C. Vespero, Maria Helena P. Rigatto, Dariane C. Pereira, Larissa Lutz, Robson S. Leão, Elizabeth A. Marques, Danielle M. Henrique, André A.M. Coelho, Lígia L. Frutuoso, Erika E. de A Sousa, Luiz F. Abreu Guimarães, Adriana L.P. Ferreira, Anna Carla Castiñeiras, Marcelle D. Alves, João Paulo Telles, Carolina H. Yamada, Francieli P. de Almeida, Evelyne S. Girão, Paulo C.P. de Sousa, Antonio G.N.D. de Melo, Elisa T. Mendes, Verônica de F.D. Rocha, Euclimeire da S. Neves, Marcello T. Ribeiro, Carlos Ernesto Ferreira Starling, Maura S. Oliveira, Jorge L.M. Sampaio, Andreza F. Martins, Afonso L. Barth, Alexandre P. Zavascki, Jéssica Nesello dos Santos, Charles Francisco Ferreira, Tarsila Vieceli, Julival Ribeiro Fagundes, Raquel Nascimento Matias, Shisue Karina Katagiri, Olavo José Vicente Neto, Rafaela Kuczynski da Rocha, Claudia Maria Dantas de Maio Carrilho, Mila Muraro de Almeida, Heloisa da Silva Rosa, Valéria Paes Lima, Tazio Vanni, Simone Aranha Nouer, Elizabeth Mendes Alves, Jorge Luiz Nobre Rodrigues, André Jhonathan Dantas, Gyselle de Souza Rebouças, Jailton Santos de Oliveira

    Published 2025-03-01
    “…In this study, we investigated the occurrence of WPAP in healthcare-associated bloodstream infections (BSI) in Brazil, an upper-middle-income country in South America. …”
    Get full text
    Article
  17. 3437
  18. 3438

    MyD88 inhibitor TJ-M2010-5 alleviates spleen impairment and inflammation by inhibiting the PI3K/miR-136-5p/AKT3 pathway in the early infection of Trichinella spiralis by Huifang Bai, Qianqian Dang, Guoliang Chen, Lingfeng Xie, Saining Wang, Ning Jiang, Xiaoxia Wu, Shuyan Zhang, Xuelin Wang

    Published 2025-02-01
    “…However, the precise mechanism of TJ-M2010-5’s involvement in spleen impairment and inflammation in the early infection of T. spiralis has yet to be fully elucidated. …”
    Get full text
    Article
  19. 3439

    Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-confirmed COVID-19 infections among healthcare workers: a multicentre, parallel-group randomised controlled trial from India by Rohina Joshi, Sudha Vidyasagar, Niveditha Devasenapathy, Rinaldo Bellomo, Vivekanand Jha, Chirag Patel, Vijay Kumar, Lachlan Donaldson, Oommen John, Balasubramanian Venkatesh, Michael John, Naomi Hammond, Jeyaraj Pandian, Ashwani Kumar, Arpita Ghosh, S Radhakrishnan, Rajib Paul, Bharath Kumar Tirupakuzhi Vijayaraghavan, Dorrilyn Rajbhandari, Sheila Nainan Myatra, Amritendu Bhattacharya, Sumaiya Arfin, Abhinav Bassi, Lachlan Hugh Donaldson, Naomi E Hammond, Mallikarjuna Kunigari, Cynthia Amrutha, Syed Haider Mehdi Husaini, Subir Ghosh, Santosh Kumar Nag, Hari Krishnan Selvaraj, Viny Kantroo, Kamal D Shah, Sheila Myatra, Amritendu Battacharya, Pavan Kumar Vecham, Evangeline Elvira, Gomathi Parthasarathy, Archana Ragunathan, Gnanavel Rajendra Kunjurao, Pavithra Sampath Kumar, Hilda Nirmala Kumari, Jayanthi Swaminathan, Murshid Cheriyeri Peediyekkal, Arun Chander Yadav, Aarthi Venkatramanan, Cynthia Amrutha Sukumar, Dharini Prasad, Krishnanda Nayak, Ravindra Prabhu, Rohini Bilagi, Akash Bhange, Bhumika Patel, Ekta Ramchandani, Jinesh Patel, Krupa Gandhi, N Prathyusha, Rayshma Rao Bonshlay Lakshmanan, S Hari Krishnan, Abhishek George Mehta, Mousumi Pradhan, Syed Haider Mehdi Husaini, Shahid Ali Siddique, Naved-ur Rahman, Mohammad Jamalludeen, Mounika Amarneni, Suresh Sankar, Vidya Rajesh Joshi, Alka Yadav, Nikhil Modi, Rinku Dahiya, Serena Knowles, Nikita Bathla, Fatima Butt

    Published 2022-06-01
    Get full text
    Article
  20. 3440

    COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) by V. T. Ivashkin, R. A. Abdulkhakov, I. G. Bakulin, S. V. Zaitsev, V. I. Luchina, S. N. Mekhtiyev, S. G. Peshekhonov, E. A. Poluektova, T. I. Semenova, S. N. Serikova, G. N. Tarasova, E. A. Trush, Y. P. Uspenskiy, I. B. Khlynov, V. V. Tsukanov, N. P. Chernus

    Published 2023-12-01
    “…Aim: to study the effectiveness and safety of using the drug Kolofort® in outpatients with irritable bowel syndrome (IBS) after a new coronavirus infection.Materials and methods. An observational non-interventional program was conducted in patients with exacerbation of IBS symptoms after a new coronavirus infection. …”
    Get full text
    Article